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The purpose of this study was the use of rhodamine 123 (Rho123) accumulation in peripheral blood CD8+c e l l sa sa
surrogate indicator to evaluate the modulating eﬀect of P-glycoprotein (P-gp) inhibitors in the multidrug resistance (MDR)
tumor-bearing mouse model. Rho123 was administered to mice, and the ﬂuorescence level in CD8+ cells was measured.
Cepharanthine hydrochloride (CH) and verapamil (VER), two P-gp inhibitors, were administered to mice 1 hour prior to Rho123
administration in vivo or added to peripheral blood 1 hour prior to Rho123 addition ex vivo. The tumor inhibition eﬀect of 5-
ﬂuorouracil/adriamycin/cisplatin (FAP) protocol plus CH was also investigated. A concentration- or dose-response relationship
was shown between the concentration and dose of CH and Rho123 accumulation or the antitumor activity. In conclusion, the
measurement of Rho123 accumulation in CD8+ cells provides a surrogate assay for the screening of candidate P-gp inhibitors in
preclinical trials, and CH is eﬀective in modulating P-gp-mediated MDR in vivo.
1.Introduction
Multidrug resistance (MDR) remains the major obstacle to
success in a wide variety of advanced malignancies, particu-
larly in solid cancers. The overexpression of P-gp is one of
the important mechanisms involved in MDR [1–3]. P-gp-
mediated cellular uptake and the eﬄux of anticancer drugs
from cancer cells are responsible for the cell elimination of
the drugs which in turn decreases their therapeutic eﬀect.
Therefore, one of the best methods of reversing MDR and
increasingtheeﬃcacyofanticancerdrugsistousethepotent
P-gpinhibitorsmodulatingP-gpfunctionand/orexpression.
It is an important step to use assays to evaluate the
eﬀect of candidate drugs as inhibitors of P-gp function in
vivo after the drugs were found to have an MDR-reversing
eﬀect in vitro. For nonsurgical solid cancer patients, there
are currently no direct assays measuring intratumoral drug
concentrations or the alteration of P-gp function and/or
expression. Thus, alternative approaches to evaluate the
degree of functional inhibition of P-gp in vivo will be a
useful aid in the development of MDR modulators. P-gp
is also expressed in normal tissues in which they seem to
have an important role in the protection against xenobiotics
[4]. Several authors reported that P-gp was expressed in
lymphocytes including CD3+,C D 4 +, and CD8+ T cells, as
well as the CD56+ natural killer (NK) cells, with the highest
expression levels and activities observed in CD56+ cells
followed by CD8+ cells [5, 6]. However, the physiological
rolesthatP-gpplaysinthesecellsareunclear.TheP-gpinthe
lymphocytes appears functionally identical to that observed
in multidrug resistant cells; they have the same substrate
and antagonist speciﬁcities [5, 7, 8]. Since the expression
and function of P-gp in CD56+ cells are the highest, is
Rho123 accumulation widely used in CD56+ populations as2 Journal of Biomedicine and Biotechnology
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Figure 1: The chemical structure of CH used in the present study.
a surrogate indicator to evaluate the degree of functional
inhibition of P-gp in clinical trials of P-gp inhibitors, for
example, the work of Tariquidar [9] and Zosuquidar [10].
As mouse NK cells do not express CD56+[11], we used
Rho123 accumulation in CD8+ cells as a surrogate indicator
to evaluate the reversal activity by P-gp reversors in the
mouse MDR tumor-bearing model.
The search for MDR modulators has extended to
the natural products and their derivatives; natural source
compounds have become the most widely used of fourth-
generation P-gp inhibitors because they are less toxic and
more potent than the disappointing ﬁrst- and second-
generation MDR modulators [12–14]. CH, manufactured
by saliﬁcation from cepharanthine, which is a biscoclaurine
alkaloid, extracted from Stephania cepharantha Hayata has a
variety of biological activities (Figure 1)[ 15–17]. Recently, it
has been reported that CH has an MDR-reversal eﬀect, and
P-gp inhibition is one of the reversal mechanisms of MDR in
vitro [18, 19]; however, the eﬀect was not evaluated in vivo.
We present here a method to detect the eﬀect of the
inhibitor of the P-gp function on Rho123 accumulations of
the CD8+ cells in whole blood from the MDR tumor-bearing
mouse. This method was ﬁrst used to develop and validate
theeﬃcacyofCHagainstP-gpfunctionsinthemousemodel
for potential use in subsequent clinical evaluations.
2.MaterialsandMethods
2.1. Animals. The experiments were carried out on 2–4-
month-old BALB/c male mice, obtained from the Henan
Experimental Animal Center (Zhengzhou, China). The ani-
mals had been raised from birth in a speciﬁc pathogen-free
environment andwerehandledaccordingtothe institutional
guidelines complying with Chinese legislation.
2.2. Cell Lines. Hca/FAP variants were developed from the
parental Hca hepatocarcinoma cells, which were obtained
from KeyGen Biotechnology Co. Ltd. (NanJing, China). By
step-by-step,continuousexposuretoincreasingdosesofFAP,
the overexpression of P-gp in the variant was conﬁrmed
by the Western blot analysis and the cells that have been
previously described [20].
2.3. Drugs. CH was supplied by the Henan Academy of
Medical and Pharmaceutical Sciences (Zhengzhou, China).
VER was purchased from Harvest Pharmaceutical Co., Ltd
(Shanghai, China). Adriamycin (ADR) was purchased from
Hisun Pharmaceutical Co., Ltd (Zhejiang, China). Cisplatin
(CDDP) was purchased from Qilu Pharmaceutical Co., Ltd
(Shandong, China). 5-Flurouracil (5-Fu) was purchased
from Xudong Haipu Pharmaceutical Co., Ltd (Shanghai,
China). Rho123 was purchased from Sigma-Aldrich (St.
Louis, Mo, USA) and dissolved in PBS at a concentra-
tion of 1mg/ml. The Ficoll-Histopaque mouse lymphocyte
separation medium was obtained from Solarbio Science &
Technology Co., Ltd (Beijing, China). The PE antimouse
CD8 antibody (clone 53-6.7) and PE Rat IgG2α, κ Isotype
CtrlwereobtainedfromBioLegend(BioLegendCorp.,USA).
All drugs were freshly prepared.
2.4. Animal Treatment. Hca/FAP cells were collected from
the ascitic ﬂuid of BALB/c mice harboring 5–7 day-old
ascitic tumor. The 1 × 107 Hca/FAP cells were injected
intramuscularly in the right axilla of BALB/c male mice
selected for the experiment on Day 0. The next day, the
animals were randomized and divided into diﬀerent groups;
each group comprised 10mice.
To study the eﬀects of Rho123 administration on periph-
eral blood CD8+ cells, the retention of ﬂuorescence in these
cells was investigated as described previously [21]w i t hs o m e
modiﬁcations and a dose-response curve established. On the
8th day after the Hca/FAP injection, the mice received a
single intravenous (i.v.) injection of Rho123. The doses used
were 0.5, 1.0, 2.5, 5.0, and 7.5mg/kg, and the volume of
administration was 10μl/g. The control group was injected
with the vehicle alone. One hour after administration,
peripheral blood was collected and cell suspension was
prepared as described below.
For the investigation of the eﬀects of P-gp inhibitors ex
vivo, blood samples were collected as described below on the
8th day after Hca/FAP injection. CH was then added at ﬁnal
concentrations of 10.0, 5.0, and 2.5μM ;V E Rw a sa d d e da ta
ﬁnal concentration of 5.0μM, an equal volume of the vehicle
wasaddedascontrol.Thesampleswereincubatedat37◦Cfor
onehourbeforeRho123wasaddedataﬁnalconcentrationof
50ng/mL, and the tubes were incubated further at 37◦Cf o r
one hour. Cell suspension was prepared as described below.
To study P-gp function in vivo, Rho123 was injected
with or without CH or VER as described before [6]w i t h
small modiﬁcations on the 8th day after Hca/FAP injection.
Brieﬂy, mice, respectively, received a single intravenous (i.v.)
injection of the vehicle as control; 2.5, 5.0, and 10.0mg/kg
of CH or 2.5mg/kg of VER followed one hour later by a
single i.v. injection of 2.5mg/kg of Rho123. The volume of
administration was 10μl/g. After one hour, blood samples
were collected and cell suspension was prepared as described
below.
2.5. Cell Preparation and Rho123 Accumulation by Flow
Cytometry. Peripheral blood was collected from the orbital
sinus of each mouse in a tube containing K2EDTA as
an anticoagulant. Mononuclear cells were obtained by the
separation of anticoagulated blood by a Ficoll-Histopaque
density-gradient centrifugation and transferred to 1.5mLJournal of Biomedicine and Biotechnology 3
Eppendorf tubes and kept on ice. Cells were washed twice
with ice-cold phosphate buﬀered saline (PBS, pH 7.4). After
that, the pellet was gently resuspended in ice-cold PBS and
adjusted to a concentration of 1 × 106 cells/ml. Single-cell
suspensions were incubated with either the PE-conjugated
antimouse CD8+ antibody or PE-conjugated Rat IgG2α, κ
Isotype Ctrl as a negative control. After staining for 30
minutes in the darkness at 4◦C, the cells were washed twice
with ice-cold PBS and then resuspended in PBS and kept on
ice in the dark until analyzed as previously described [22].
Al i f e - g a t eb a s e do nf o r w a r ds c a t t e r( F S C )a n ds i d es c a t t e r
(SSC) parameters were made to analyze only viable cells;
other gates were made to determine the subpopulations.
Ampliﬁer settings for FSC and side SSC were used in
linear mode and those for ﬂuorescence channels were used
in a logarithmic mode. Fluorescence compensation was
manually set for FL1 channel (Rho123) and FL2 channel
(PE) with single Rho123-stained cells and PE-stained cells
separately. At least 30,000 events were acquired per sample.
Multicolor ﬂow cytometry analyses were used to evaluate
the proportions of the CD8+ population and the mean
ﬂuorescenceintensity(MFI)ofRho123inthepopulation.All
analyses were performed in duplicate in at least four separate
experiments.CellswereanalyzedonEpics-XLMCL,anddata
wereanalyzedwithExpo32ADCsoftware(BeckmanCoulter,
Fullerton, Calif, USA).
2.6. Tumor Inhibition of FAP Chemotherapy Protocol plus
CH. To evaluate the antitumor eﬀect of FAP chemotherapy
protocol plus various concentrations of CH or VER in vivo
as previously described [23]. Twenty four-hours after the
Hca/FAP injection, the mice were randomly divided into
diﬀerent groups and treated as follows:
Group I: control (normal saline i.v. injected consecu-
tively from Day 1 to 9),
Group II: 10mg/kg of CH alone i.v. injected from Day 1
to 8,
Group III: FAP chemotherapy: 4.2mg/kg of ADR and
85.0mg/kg of 5-FU i.v. injected on Day 1,
2.8mg/kg of CDDP i.v. injected from Day 1 to
8,
Group IV: 2.5mg/kg of CH i.v. injected from Day 1 to 8
with FAP chemotherapy,
Group V: 5.0mg/kg of CH i.v. injected from
Day 1 to 8 with FAP chemotherapy,
Group VI: 10.0mg/kg of CH i.v. injected from Day 1 to 8
with FAP chemotherapy,
Group VII: 2.5mg/kg of VER i.v. injected from Day 1 to 8
with FAP chemotherapy.
The volume of administration was 10μl/g. Tumors were
resected on the second day following the last injection. The
tumor length (L) and width (W) were measured, and the
tumor weight (WR) was calculated as follows:
WR =
1
2
× L × W2. (1)
R2 = 0.9942
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Figure 2: Mean ﬂuorescence intensities of CD8+ cells were linearly
correlated to the dose of Rho123 administered (r2 = 0.9942). The
treatment protocol and experimental procedures are described in
the text. Responses to treatments were signiﬁcantly diﬀerent from
each other (P<. 05).
The percent of tumor growth inhibition was calculated on
Day 8 by comparing the average values of the treated groups
with those of the tumor-bearing control group. Tumor
growth in saline treated control animals was taken to be at
100%.
2.7. Statistical Analysis. For all the experiments, data are
presented as the mean ± SD. Statistical comparison between
thegroupswithdiﬀerentdosesorconcentrationswascarried
out using two-sided Student’s t-tests. Tests for signiﬁcant
diﬀerences among the groups were done using one-way
ANOVA with multiple comparisons (Fisher’s pairwise com-
parisons) using SPSS 13.0 (IBM software, Somers, NY, USA).
A minimum P value of .05 was estimated as the signiﬁcance
level for all tests.
3. Results
The i.v. administration of Rho123 (0.5–7.5mg/kg) in mice
produced a dose-dependent ﬂuorescence fashion in periph-
eralbloodCD8+ cells(Figure 2).Alldoseswerewelltolerated
without signiﬁcant toxicity.
The lower dose of Rho123, 2.5mg/kg, was selected to
investigate the eﬀects of CH on the accumulation of Rho123
in peripheral blood CD8+ cells. Using this dose, Rho123
accumulations were increased after administration of either
VER (positive control) or CH and presented a clear dose-
dependent relationship with CH (2.5–10mg/kg) compared
with vehicle control, as shown in Figure 3. The eﬃcacy of4 Journal of Biomedicine and Biotechnology
Table 1: The Tumor inhibition of the Hca/FAP solid tumor after treatment.
Treatment groups Avg. tumor weights (mg) %Tumor growth inhibition Mortality
FAP+CH 10.0mg/kg 248.0 ± 88.0∗ 71.4% 0/10
FAP+CH 5.0mg/kg 364.0 ± 82.2∗ 57.9% 0/10
FAP+CH 2.5mg/kg 479.0 ± 96.8∗ 44.7% 0/10
FAP+VER 2.5mg/kg 482.8 ± 59.4∗ 44.2% 2/10
FAP 479.0 ± 187.5∗ 44.7% 0/10
CH 10.0mg/kg 689.0 ± 104.8∗ 20.4% 0/10
Control 866.0 ± 153.3 — 0/10
∗P<. 05, diﬀerent from the control, no signiﬁcant diﬀerence from each other (P>. 05).
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Figure 3: Accumulation of Rho123 in CD8+ cells by diﬀerent doses
of reversors with or without Rho123 at a dose of 2.5mg/kg in vivo.
The increase of the mean ﬂuorescence intensity that reﬂects the
eﬄux is inhibited. ∗P<0.05, diﬀerent from the control. The results
are the mean ± SD of at least 4 independent experiments.
the P-gp reversors was not equal; VER was less eﬃcient and
potent than CH. There has similar result in ex vivo blood
samples; the MFIs of CD8+ cells in the samples treated with
the vehicle, 5.0μM of VER and 2.5, 5.0 and 10.0μMo fC H
were 14.4 ± 0.3, 20.0 ± 0.3, 22.9 ± 0.5, 25.4 ± 1.0 and 29.8
± 0.9, respectively. The MFI was related to the presence of
CH in a concentration pattern in ex vivo blood samples, as
shown in Figure 4. This demonstrated that P-gp is active in
CD8+ cells and can be modulated by CH in vivo and ex vivo.
TheantitumoreﬀectsofFAPcombinationchemotherapy
plus i.v. 2.5mg/kg of VER or 2.5, 5.0, and 10.0mg/kg of
CH were evaluated in the Hca/FAP tumor-bearing mouse.
The FAP combination chemotherapy plus 10.0mg/kg of CH
provided the maximum antitumor activity of the treatments
studied. Compared with the FAP chemotherapy group,
the antitumor eﬀect was increased in a dose-dependent
manner when the FAP combined chemotherapy plus various
concentrations of CH was used, as shown in Table 1. This
suggested that the MDR resistance was reversed by CH in
vivo.
4. Discussion
Hepatocellular carcinoma (HCC) represents the third lead-
ing cause of cancer-related death [24]. Chemotherapy con-
sisting of FAP was commonly used to treat HCC in clinical
situations [25]; however, HCC is often resistant to these
drugs. Therefore, one of the key approaches is to overcome
drug resistance in the success of chemotherapy against HCC.
PreviousstudiesofP-gpinhibitorssuchasVER,cyclosporine
A, and its analog PSC833 [26–28] have been limited because
of its serious toxicity at the time of dosage for reversing drug
resistance.
An important step to develop the MDR reversors tar-
geting P-gp is to determine the inhibition level of P-gp in
the preclinical animal model. An ideal approach is to detect
the real concentrations of the investigated drug directly in
vivo, but it is almost impossible, even in the animal model.
If there is no related data on the inhibition level of P-gp,
it is diﬃcult to interpret the eﬃcacy of P-gp inhibitors in
pre- or clinical trials. Recently, the functional study of P-
gp was of great concern. Among lymphocytes in the mouse,
CD8+ cells expressed the highest levels of P-gp followed
by CD4+ > CD3+ [6, 21, 29–32]. Since blood samples are
easy to be collected, we selected peripheral blood CD8+ cells
as a surrogate indicator to investigate the alteration of P-
gp activities before and after the administration of P-gp
inhibitors and then evaluate the reversal eﬀect of the drug
in a solid-tumor-bearing mouse. Rho123 is a ﬂuorescent
substrateand has been shown to be a sensitive reagentfor the
detection of P-gp function by ﬂow cytometry [14, 33]. Some
authors reported that Rho123 was a substrate for MRP andJournal of Biomedicine and Biotechnology 5
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Figure 4: Rho123 accumulations in CD8+ cells ex vivo, where the grey lines stand for cells treated with Rho123 plus the vehicle and it was
set as the control in the four sub-ﬁgures and the black lines represent cells treated with Rho123 in the presence of various concentrations
reversors:A.VER5.0μM,B.CH2.5μM,C.CH5.0μM,D.CH10.0μM.Thisﬁgureisrepresentativeofatleastfourindependentexperiments.
P-gp [34], but Leite et al. [6] reported that classical MRP1
reversors were unable to enhance Rho123 accumulation in
lymphocytes suggesting that MRP1 might not be active or
Rho123 is not a good substrate for MRP1 expressed in
these cells. Therefore, the alteration of Rho123 ﬂuorescence
intensities in these cells responded to the alteration of the P-
gp function. In this study, we demonstrated that the mean
ﬂuorescence intensities of CD8+ cells were related to the dose
of Rho123 in a dose-dependent manner suggesting that it is
a good choice to use the accumulation of Rho123 in CD8+
cells as a surrogate indicator for the study of P-gp inhibitors.
We further studied the modulation eﬀect of CH in
vivo and ex vivo; the results showed that the mean ﬂuo-
rescence intensities of CD8+ c e l l sw e r er e l a t e dt oC Hi n
a dose- or concentration-dependent manner either in vivo
or ex vivo. This suggested that the activities of P-gp were
inhibited by CH. In our previous study, it was shown that
the enhancement of cytotoxicity of FAP against cultured
Hca/FAPcellsbyCHoccursinvitro;theeﬄuxrateofRho123
in Hca/FAP cells was 2 times less than that of Hca cells
a f t e r1h o u re x p l o s u r et oC Hp l u sF A P .W eh a v ed e t e r m i n e d
the LD50 for i.v. mice is 0.47 times of clinical dosing of
FAP protocol, that is, 85.0mg/kg of 5-FU, 4.2mg/kg of
ADR, and 2.8mg/kg of CDDP [20]. In the present study,
we established an Hca/FAP solid tumor mouse model and
assessed the antitumor eﬀect of FAP combination protocol
plus CH. The i.v. dosing for a mouse is 42.50mg/kg of 5-Fu,
2.10mg/kgofADR,1.40mg/kgofCDDP.Theresultsshowed6 Journal of Biomedicine and Biotechnology
Table 2: Body weights of the animal after treatment.
Treatment groups Body weights (g)
Day 1 Day 4 Day 8
FAP+CH 10.0mg/kg 25.9 ± 1.4 25.6 ± 1.3 25.1 ± 1.2
FAP+CH 5.0mg/kg 25.2 ± 1.6 25.0 ± 1.6 24.7 ± 1.8
FAP+CH 2.5mg/kg 25.0 ± 1.9 24.5 ± 1.9 23.8 ± 2.1
FAP+VER 2.5mg/kg 25.1 ± 1.2 25.0 ± 1.1 24.3 ± 1.3
FAP 25.5 ± 1.8 24.6 ± 1.7 24.6 ± 1.5
CH 10.0mg/kg 24.9 ± 1.3 25.0 ± 1.0 24.9 ± 0.9
Control 25.3 ± 1.2 25.8 ± 1.4 26.9 ± 1.9
that a single i.v. dose of 10.0mg/kg CH partly inhibited the
tumor growth, but the eﬀect was weak; this is consistent
with conclusions drawn from other authors’ reports [35]:
a single i.v. dose of 5.0mg/kg CH has no antitumor eﬀect
(data not shown). When FAP combined chemotherapy plus
various concentrations of CH was used, the antitumor eﬀect
was increased in a dose-dependent manner. Therefore, with
this correlation with the results of the inhibition of P-gp
function by CH in CD8+ cells, we think that the antitumor
activity recovered by CH in a dose-dependent manner was
related to the inhibition of the P-gp function. All of the
eﬃcacious combination protocols with CH appeared to
be well tolerated, as indicated by the minimal changes in
body weights of the various treatment groups (as shown in
Table 2). Since an LD50 of VER for the i.v. administration in
mouse was reported to be 7.6mg/kg [36], but a single i.v.
dose of 5.0mg/kg VER caused the death of 60% of animal in
the treated BALB/c mice (data not shown), we selected the
dose of 2.5mg/kg as a positive control. There is no mortality
in the FAP treated group; we think the 20% mortality in the
FAP plus VER treated group was caused by the increasing
toxicity when VER combined with ADR [37].
Although one can argue that what occurs at the level
of peripheral blood CD8+ cells may not accurately reﬂect
the real inhibition level of P-gp in the solid tumor in
mouse, 99mTc-sestamibi scans performed in some studies
have shown eﬀective P-gp inhibition in both normal tissues
and solid tumors [9, 38], suggesting the inhibition level
of P-gp was modulated simultaneously. We have to note
that no model is perfect and there are obvious diﬀerences
between humans and mice; the BALB/c mouse is unique
for its features, making even more diﬃcult extrapolations to
human conditions.
With regard to the results obtained, we conclude that CH
is a potent P-gp inhibitor for clinical application. Although
limitations may exist in the surrogate assay in CD8+ cells
in the mouse model, we are convinced that this assay
can provide us with much useful information in screening
potential P-gp inhibitors in vivo.
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